DexCom, Inc. (NASDAQ:DXCM) Shares Purchased by PKO Investment Management Joint Stock Co

PKO Investment Management Joint Stock Co increased its holdings in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 89.6% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 91,000 shares of the medical device company's stock after buying an additional 43,000 shares during the period. PKO Investment Management Joint Stock Co's holdings in DexCom were worth $6,214,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also made changes to their positions in DXCM. Brighton Jones LLC increased its position in shares of DexCom by 257.7% during the fourth quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company's stock worth $1,290,000 after purchasing an additional 11,946 shares in the last quarter. Empowered Funds LLC increased its position in shares of DexCom by 37.0% during the fourth quarter. Empowered Funds LLC now owns 8,010 shares of the medical device company's stock worth $623,000 after purchasing an additional 2,163 shares in the last quarter. Allspring Global Investments Holdings LLC increased its position in shares of DexCom by 28.8% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 58,571 shares of the medical device company's stock worth $4,596,000 after purchasing an additional 13,111 shares in the last quarter. Van ECK Associates Corp increased its position in shares of DexCom by 325.0% during the fourth quarter. Van ECK Associates Corp now owns 85,813 shares of the medical device company's stock worth $6,674,000 after purchasing an additional 65,622 shares in the last quarter. Finally, Bank Pictet & Cie Europe AG grew its holdings in shares of DexCom by 1.8% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 111,063 shares of the medical device company's stock valued at $8,637,000 after buying an additional 2,010 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at DexCom

In related news, EVP Michael Jon Brown sold 10,000 shares of the company's stock in a transaction dated Friday, May 23rd. The shares were sold at an average price of $84.28, for a total transaction of $842,800.00. Following the completion of the transaction, the executive vice president now owns 95,602 shares in the company, valued at $8,057,336.56. This represents a 9.47% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Nicholas Augustinos sold 3,672 shares of the company's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $82.80, for a total transaction of $304,041.60. Following the transaction, the director now owns 33,411 shares of the company's stock, valued at approximately $2,766,430.80. This trade represents a 9.90% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 22,474 shares of company stock valued at $1,887,026 in the last ninety days. 0.32% of the stock is currently owned by corporate insiders.

DexCom Price Performance

Shares of DXCM stock traded down $0.64 during mid-day trading on Wednesday, hitting $81.19. 1,049,966 shares of the stock were exchanged, compared to its average volume of 4,332,638. The firm has a fifty day moving average of $79.25 and a 200 day moving average of $79.38. The company has a quick ratio of 1.32, a current ratio of 1.50 and a debt-to-equity ratio of 0.55. DexCom, Inc. has a 52-week low of $57.52 and a 52-week high of $117.49. The company has a market cap of $31.84 billion, a PE ratio of 60.64, a price-to-earnings-growth ratio of 1.77 and a beta of 1.46.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.01). DexCom had a return on equity of 30.05% and a net margin of 12.90%. The firm had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.02 billion. During the same period in the previous year, the company earned $0.32 earnings per share. The company's revenue was up 12.5% compared to the same quarter last year. Research analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on DXCM. Cfra Research raised shares of DexCom to a "hold" rating in a report on Friday, March 21st. Wall Street Zen raised shares of DexCom from a "hold" rating to a "buy" rating in a report on Friday, June 6th. Robert W. Baird dropped their price objective on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a report on Friday, May 2nd. Mizuho began coverage on shares of DexCom in a report on Thursday, April 10th. They set an "outperform" rating and a $85.00 price objective on the stock. Finally, Wells Fargo & Company reissued an "overweight" rating on shares of DexCom in a report on Saturday, March 8th. Four analysts have rated the stock with a hold rating, sixteen have given a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $98.50.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.